High-throughput Screening Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The High-throughput Screening Market is segmented by Technology (Ultra-high-throughput Screening, Cell-based Assays, Lab-on-a-chip and Label-free Technology), Application (Target Identification, Primary Screening, and Toxicology), Products and Services, End User, and Geography.

High-throughput Screening Market Snapshot

high throughput screening market analysis
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.8 %
high throughput screening (hts)market major players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The high-throughput screening market studied was anticipated to grow with a CAGR of nearly 7.8% during the forecast period. The high-throughput screening (HTS) centers in the public domain have increased significantly over the past decade, ranging in size, from modestly-equipped academic screening centers to well-endowed molecular libraries probe centers network (MLPCN). These centers facilitate a comprehensive approach to probe discovery in academia, and utilize, both, standard and innovative assay technologies for executing primary and secondary screening campaigns. One of the significant advantages of these centers was knowledge sharing among scientists, researchers, etc. In European countries, EU-open-screen, European counterpart of US NIH initiative, is also working to get open access to all European organizations involved in chemical biology. Additionally, the association of HTS centers is also emerging, which is aimed at sharing valuable information about the compound or target, or the whole process. The open access provides a better platform for knowledge sharing, and can help optimize the entire process, which may drive the demand for HTS technology among end users.

HTS systems allow tens of thousands or even hundreds of thousands of compounds to be evaluated in a single day. As the throughput increases, the amount of data for each experiment increases, and scientists analyze and derive results from large amounts of data. Due to the sheer number of samples being processed and the massive volume of data being produced, the need for extensive automation techniques arises, to streamline the operations. However, automation requires massive investments for the establishment of machinery and supporting architecture, which are roadblocks for small- and moderate-size research institutes. Thus, the high costs associated with automation techniques can limit the market expansion.

Scope of the Report

The high-throughput screening market has been segmented by technology, applications, products and services, end user, and geography. By technology, the market is divided into an ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technology. By application, the market has been subdivided into target identification, primary screening, and toxicology. By products and services, the market has been segmented into instruments, reagents and kits, and services. By end user, the market has been segmented into pharmaceutical and biotechnology firms, academia and research institutes, and contract research organizations.

By Technology
Ultra-high-throughput Screening
Cell-based Assays
Label-free Technology
By Applications
Target Identification
Primary Screening
By Products and Services
Reagents and Kits
By End User
Pharmaceutical and Biotechnology Firms
Academia and Research Institutes
Contract Research Organizations
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East & Africa
South Africa
Rest of Middle-East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Pharmaceutical and Biotechnology Firms Represent the Largest End Users of High-throughput Screening Modalities.

In order to gain sustainable competitive advantage, most of the large and small biotechnology and pharmaceutical companies are focusing on the development of novel molecules for the treatment of several chronic conditions. Furthermore, FDA’s Center for Drug Evaluation and Research’s (CDER’s) new drug therapy approvals helped a wide range of patients suffering from many different medical conditions. The need for rapid and precise screening of several target molecules, during drug discovery and development phases, has led to the adoption of automated high-throughput screening techniques to screen massive chemical and biomarker libraries generated during the research processes. Since an automated HTS system can test 10,000 to 100,000 target compounds per day, and uHTS can test more than 100,000 compounds per day, their adoption for drug discovery and development process has resulted in the market expansion.

high throughput screening (hts)market trends

North America is Expected to Dominate the Market

North America dominates the global high-throughput screening market, owing to the high adoption rate of HTS in the United States. The growth of the US high-throughput screening market can be attributed to the significant advances in combinatorial chemistry and the field of genomics. In addition, huge investments by the pharmaceutical industry, for HTS technologies, in terms of automation, miniaturization, and assay methodology, have further helped in the growth of the market. 

high throughput screening (hts)market share

Competitive Landscape

The high-throughput screening market is highly competitive and consists of several major players. Most of the major players enjoy a global presence, and are facing intense competition in emerging economies. The emerging countries are becoming hotspots of significant competition, due to a rapidly expanding market size, fueled by growing investments in R&D and the recent trend of contract research outsourcing. 

Recent Developments

In June 2021, Bio-Rad Laboratories, Inc. partners with Seegene, Inc., for the clinical development and commercialization of infectious disease molecular diagnostic products and expand its presence in the high-throughput screening market.

In March 2020, Danaher Corporation acquired the Biopharma business from General Electric Company's Life Sciences division. As part of Danaher, the business will be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Open Access to High-throughput Screening Laboratories

      2. 4.2.2 Technological Advancements in HTS

      3. 4.2.3 Increasing Usage in Universities and Research Centers

    3. 4.3 Market Restraints

      1. 4.3.1 High Capital Investment

      2. 4.3.2 Need for Extensive Automation Techniques

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Technology

      1. 5.1.1 Ultra-high-throughput Screening

      2. 5.1.2 Cell-based Assays

      3. 5.1.3 Lab-on-a-chip

      4. 5.1.4 Label-free Technology

    2. 5.2 By Applications

      1. 5.2.1 Target Identification

      2. 5.2.2 Primary Screening

      3. 5.2.3 Toxicology

    3. 5.3 By Products and Services

      1. 5.3.1 Instruments

      2. 5.3.2 Reagents and Kits

      3. 5.3.3 Services

    4. 5.4 By End User

      1. 5.4.1 Pharmaceutical and Biotechnology Firms

      2. 5.4.2 Academia and Research Institutes

      3. 5.4.3 Contract Research Organizations

    5. 5.5 Geography

      1. 5.5.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.5.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.5.4 Middle-East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East & Africa

      5. 5.5.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Agilent Technologies Inc.

      2. 6.1.2 Axxam SpA

      3. 6.1.3 Beckman Coulter Inc.

      4. 6.1.4 Bio-Rad Laboratories Inc.

      5. 6.1.5 Danaher Corporation

      6. 6.1.6 GE Healthcare

      7. 6.1.7 Merck KGaA

      8. 6.1.8 PerkinElmer Inc.

      9. 6.1.9 Tecan Group Ltd

      10. 6.1.10 Thermo Fisher Scientific Inc.

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The High-throughput Screening Market market is studied from 2018 - 2026.

The High-throughput Screening Market is growing at a CAGR of 7.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Agilent Technologies Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., Thermo Fisher Scientific Inc. are the major companies operating in High-throughput Screening Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!